DRUG
Bright Minds·NASDAQ
--
--(--)
--
--(--)
5.38 / 10
Netural
Analyst sentiment is overwhelmingly bullish with four Strong Buy ratings, but historical win rates vary widely (33-100%). Fund flow is robust (7.42/10) with positive small- and medium-scale inflows, although block and large-scale flows lean negative. This divergence underscores cautious optimism: strong retail interest and analyst conviction offset limited institutional support.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-30
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate100.0%
What is the analyst consensus for DRUG?
- DRUG holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.38/10 (Netural).
